Kyle Munz

The American Heart Association’s (AHA) centennial event brought together a plethora of diverse perspectives spanning the field of cardiology, nephrology, radiology, and more. Scientific and educational sessions alike at this year’s meeting underscored the transformative potential of multidisciplinary collaboration, holistic […]

The FDA approved mavacamten (Camzyos), a cardiac myosin inhibitor, for the treatment of adult patients with New York Heart Association class II to III obstructive hypertrophic cardiomyopathy (HCM) in 2022. Milind Desai, MD, MBA, Cleveland Clinic, reported on the drug’s

Heart failure remains a serious complication, contributing to great rates of morbidity and mortality in affected patients. Persistent disparities in heart failure have reinforced the need to take a closer look at why some populations bear the brunt of disease

Developments in atherosclerosis were among the many novel points of progress highlighted at this year’s American Heart Association (AHA) conference. As the latest research sheds light on the new pathways, therapeutic possibilities, and mechanisms associated with vascular disease, Masanori Aikawa,

Women carry more risk for heart failure with preserved ejection fraction (HFpEF); however, female representation in clinical trials for heart failure remains overwhelming insufficient. New data from the FINEARTS-HF trial, which evaluated the safety and efficacy of finerenone (Kerendia), offers

The time has for cardiovascular medicine to form its very own certifying board. As the American Board of Medical Specialties (ABMS) weighs over submitting a formal application, the creation of an American Board of Cardiovascular Medicine (ABCVM) has the potential

The American Heart Association (AHA) was founded in 1924. As such, this year’s AHA conference held in Chicago, Illinois, will mark 100 years of the organization’s existence. The AHA Scientific Sessions will be held November 16-18 and feature research from

Brief cognitive behavioral therapy (BCBT) can effectively lower rates of suicidal ideation and suicide attempts, according to new research published in JAMA Open Network that evaluated the effectiveness of telehealth-delivered BCBT.1 Suicide remains a pertinent public health concern, with the

Today, Insilico Medicine announced encouraging results from their phase 2a trial (NCT05938920) on the use of ISM001-055 for treating patients with idiopathic pulmonary fibrosis (IPF). These results have thus far demonstrated the tolerability and safety of the medication, as well